ISA Pharmaceuticals B.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ISA Pharmaceuticals B.V.
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
Armed with €26m in fresh funds from investors that include partner Regeneron, ISA Pharma can now advance promising preclinical assets generated from its proprietary platform, containing a mix of synthetic antigenic peptides, its CEO tells Scrip.
Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.
ISA Pharmaceuticals and Regeneron have updated their collaboration to outline a potential path to market for a combination of an anticancer immunotherapeutic and the checkpoint inhibitor, cemiplimab, for HPV-associated head-and-neck cancer.
- Drug Delivery
- Drug Discovery Tools